Asthma and COPD Drugs Market worth $50,359 Million by 2022
Global Asthma and COPD Drugs Market was valued at $38,960 million in 2015 and would reach $50,359 million by 2022, registering a CAGR of 3.7% from 2016 to 2022, according to a new report published by Allied Market Research.Asthma segment dominated the market in 2015 and expected to continue its dominance throughout the forecast period. North America accounted around for around half of the Global Asthma and COPD Drugs market share in 2015.
Get Access to TOC / Sample Report @ https://www.alliedmarketresearch.com/request-sample/311?utm_source=OPR
Increase in incidence and prevalence of asthma and COPD, growing geriatric population, technological advancement in the treatment of asthma and COPD diseases, growth in initiatives implemented by the government and non-government associations around the Global are the factors that majorly drive the growth of this market. However, stringent government regulations for the product approval, patent expiry of branded drugs, and side effects associated with drugs restrict the market growth.
In 2015, the asthma segment accounted for over 65% share of the overall Asthma and COPD Drugs market. Increase in introduction of generic drugs, and rising prevalence of asthma coupled with geriatric population and changes in lifestyle are the major factors that attribute to the rise in growth of this market.
Among the medication classes, the combination products segment held major share of the Global COPD and asthma drug market in 2015. This segment is expected to maintain its leading position in the overall market throughout the analysis period, primarily because of increase in focus on the effective asthma and COPD management and increase in the research and development of innovative treatment of the diseases.
North America led the market share in 2015, and is expected to maintain this lead throughout the forecast period. The growth in the Asthma and COPD Drugs market in these regions attributes to the increase in the asthma and COPD patients, technological advancement in the treatment. However, Asia-Pacific is projected to be the fastest-growing region, registering a CAGR of 5.1% during the analysis period. This is mainly due to the increase in adoption rate for the technological advancement for treating asthma and COPD diseases. In addition, increase in research outsourcing from emerging markets, improvement of healthcare infrastructures, and increase in expenditures in the emerging markets (such as India and China) have boosted the market growth.
Send Enquiry on this report @ https://www.alliedmarketresearch.com/purchase-enquiry/311?utm_source=OPR
Key findings of Asthma and COPD Drugs Market:
• In 2015, COPD was the leading segment of overall Asthma and COPD Drugs market revenue, and is projected to grow at a CAGR of 7.5% during the forecast period.
• Anticholinergics segment is expected to grow at a remarkable CAGR of 6.7%, owing to increased and effective treatment of the disease.
• North America led the Global Asthma and COPD Drugs market in 2015.
• The combination products segment is projected to be the largest revenue-generating medication class segment.
• Japan alone is the major shareholder in the Asia-Pacific region accounting for over two-fifths share of the Asia-Pacific Asthma and COPD Drugs market.
The key players in the Asthma and COPD Drugs market are highly focused on expanding their business operations in the fast-growing emerging countries with new product launches as the preferred strategy. The key players profiled in this report include GlaxoSmithKline (GSK) (U.K), Novartis AG (Switzerland), Merck & Co. (U.S), Abbott Laboratories (U.S), Boehringer Ingelheim (Germany), AstraZeneca (U.K), Roche Holding AG (Switzerland), Teva Pharmaceutical Industries(Israel), Vectura Group (U.K), and Pfizer Inc. (U.S).
Allied Market Research, a market research and advisory company of Allied Analytics LLP, provides business insights and market research reports to large as well as small & medium enterprises. The company assists its clients to strategize business policies and achieve sustainable growth in their respective market domain.
Allied Market Research provides one stop solution from the beginning of data collection to investment advice. The analysts at Allied Market Research dig out factors that help clients to understand the significance and impact of market dynamics. The company amplies client’s insight on the factors, such as strategies, future estimations, growth or fall forecasting, opportunity analysis, and consumer surveys among others. As follows, the company offers consistent business intelligent support to aid the clients to turn into prominent business firm.
5933 NE Win Sivers Drive
#205, Portland, OR 97220
Toll Free (USA/Canada):
+1-800-792-5285, +1-503-894-6022, +1-503-446-1141
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
This release was published on openPR.
Permanent link to this press release:
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Asthma and COPD Drugs Market worth $50,359 Million by 2022 here
News-ID: 1377634 • Views: 536
More Releases from Allied Market Research
Smart Beacon Market Expected to Reach $103.94 Billion By 2030 at 37.7% CAGR | Gr …
Rise in modern-day communication technologies, surge in investments in proximity marketing, and increase in adoption of smart devices are the factors that drive the global smart beacon market growth. As per the report published by Allied Market Research, the global smart beacon market generated $3.28 billion in 2020, and is estimated to reach $103.94 billion by 2030, witnessing a CAGR of 37.7% from 2021 to 2030. The report provides a
Fantasy Sports Market in Asia-Pacific & Canada is Expected to Reach $3,739.8 Mil …
According to a new report published by Allied Market Research, titled, “Asia-Pacific & Canada Fantasy Sports Market by Sports Type, Platform, and Demographic: Regional Opportunity Analysis and Industry Forecast, 2021–2027,” Asia-Pacific & Canada fantasy sports market size was valued at $2,021.9 million in 2019, and is projected to reach $3,739.8 million by 2027, growing at a CAGR of 10.7% from 2021 to 2027. Fantasy sport is played using internet where participants
Hammock Market Size Is Projected Reach $639.8 Million By 2030, Registering At A …
Surge in hiking and adventure tourism, rise in demand from residential segment, and expansion of hospitality industry drive the growth of the global hammock market. North America contributed to the highest share in terms of revenue in 2020. The outbreak of the COVID-19 pandemic has resulted in transition of consumers toward online sales channels to purchase campaigning gear products including hammocks. According to the report published by Allied Market Research, the
Cotton Personal-Care Product Market 2021: Top Factors That Are Leading The Deman …
A lead analyst at AMR highlighted the market across Europe region is expected to dominate in terms of revenues throughout the forecast period. Allied Market Research published a research report on the Cotton personal-care product market. The findings of the report states that the global market for Cotton personal-care product is expected to reach $19.15 billion by 2028, manifesting a CAGR of 4.6% from 2020 to 2028. The report provides valuable
More Releases for COPD
COPD Therapeutics Global Market Research Report 2019
COPD Therapeutics Report by Material, Application, and Geography � Global Forecast to 2022 is a professional and in-depth research report on the world's major regional market conditions, focusing on the main regions (North America, Europe and Asia-Pacific) and the main countries (United States, Germany, united Kingdom, Japan, South Korea and China). Access more details about this report at: https://www.research2reports.com/report-medical-devices/copd-therapeutics-market/80858 The report firstly introduced the COPD Therapeutics basics: definitions, classifications, applications and market
Alarming Prevalence of COPD to Propel Oxygen Therapy Devices Market
"Oxygen therapy equipment market driven by increasing urbanization and rising levels of air pollution." An intelligence report on the global oxygen therapy equipment market has been added to the burgeoning portfolio of MarketResearchReports.biz. Titled, “Global Oxygen Therapy Equipment Market - Analysis By Product, Portability, Application, Region, Country: Opportunities and Forecast (2017- 2022) - By Product (Oxygen Concentrators, Liquid Oxygen Devices and Oxygen Cylinders), By Portability (Stationary, Portable Devices), By Application (COPD,
Asthma and COPD Drugs Market | Key Opportunities And Forecast 2024
The top five companies in the U.S. and China Asthma And Copd Drugs Market accounted for just under 64.0% in 2015, hinting at not just the consolidated nature of this industry but also at the immense competition among players. GlaxoSmithKline plc, Astrazeneca plc, Boehringer Ingelheim, Merck & Co. Inc., and Novartis AG currently enjoy the leading spots in the asthma and COPD drugs market. According to Transparency Market Research, the opportunity
Global COPD and Asthma Devices Market Size
According to a new report, Global COPD and Asthma Devices Market, published by KBV Research, The Global COPD and Asthma Devices Market attained a market size of $ 27,465.1 Million in 2015 and is expected to reach $ 39,051.4 Million by 2022 growing at a CAGR of 5.2 % CAGR during 2016 – 2022. The Asia Pacific market dominated the Global COPD and Asthma Devices Market in 2015 and would
COPD Drug Market Opportunity & Clinical Pipeline Analysis
Close to 1 Billion people worldwide suffer from respiratory or pulmonary diseases. In the respiratory therapeutic domain, Asthma and COPD are the major categories, accounting for close to 75% of the total patient for respiratory or pulmonary diseases. Chronic obstructive pulmonary disease (COPD) is a disease which progresses in the lungs and requires treatment all through the life. It is an inflammatory disorder which is characterized by obstruction in the
Global COPD inhalers Industry:-Forecast 2022
Chronic Obstructive Pulmonary Disease (COPD) is a wide term used for progressive lung diseases which includes chronic bronchitis, emphysema, refractory asthma, and some forms of bronchiectasis. The symptoms of COPD includes recurrent coughing with or without sputum, difficulty in breathing, wheezing and tightness in the chest due to the blockage of lungs’ airways. More than 70 million people in the world are suffering from COPD as of 2015, majority of